The legitimacy auction

When a regulator weighs whether to permit a therapy that millions already use, that decision can be read as an implicit claim about what counts as medicine. The FDA's two-day Pharmacy Compounding Advisory Committee meeting this week sits at that hinge. Seven synthetic peptides, customized versions of approved drugs like semaglutide made by specialty pharmacies or sold online, sit between an unregulated gray market and a formal evidence system. The committee only recommends. The harder question is whether the agency should widen access before the science catches up.

Jason Nagata, a University of California San Francisco pediatrics professor and co-author of a JAMA editorial on peptides' regulatory gaps, named the public-health stakes: "The key public health question is whether these products should become more widely available before that evidence exists." Three forces are pulling on the panel: career FDA scientists who want stronger evidence, newly appointed members with ties to peptide-prescribing clinics, and HHS leadership broadly sympathetic to expanded access. Whichever side wins, the gray market's compounds receive the FDA's implicit or explicit endorsement.

Compounded peptides are not a one-off. The same dynamic — an FDA decision reframed as a statement about medical legitimacy — is likely to recur wherever off-label demand outruns trials.